Discovery of Non-Cysteine-Targeting Covalent Inhibitors by Activity-Based Proteomic Screening with a Cysteine-Reactive Probe
- ACS Chem Biol. 2022 Feb 18;17(2):340-347. doi: 10.1021/acschembio.1c00824.
- 1. Institute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan.
- 2. Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
- 3. School of Pharmacy, Fudan University, Shanghai 201203, China.
- 4. Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Uji, Kyoto 611-0011, Japan.
Covalent inhibitors of Enzymes are increasingly appreciated as pharmaceutical seeds, yet discovering non-cysteine-targeting inhibitors remains challenging. Herein, we report an intriguing experience during our activity-based proteomic screening of 1601 reactive small molecules, in which we monitored the ability of library molecules to compete with a cysteine-reactive iodoacetamide probe. One epoxide molecule, F8, exhibited unexpected enhancement of the probe reactivity for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a rate-limiting glycolysis enzyme. In-depth mechanistic analysis suggests that F8 forms a covalent adduct with an aspartic acid in the active site to displace NAD+, a cofactor of the enzyme, with concomitant enhancement of the probe reaction with the catalytic cysteine. The mechanistic underpinning permitted the identification of an optimized aspartate-reactive GAPDH inhibitor. Our findings exemplify that activity-based proteomic screening with a cysteine-reactive probe can be used for discovering covalent inhibitors that react with non-cysteine residues.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Endogenous MetaboliteResearch Areas: Metabolic Disease